http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015079033-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be580cf71e5093430b1d31b0fdfe3dc8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96494 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2014-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b102324f75c30337e13892f69887130 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_481904a3cac9e7eb7f6c114e62963085 |
| publicationDate | 2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2015079033-A1 |
| titleOfInvention | Detection of bladder cancer and recurrent bladder cancer |
| abstract | The non-invasive methods described herein generally relates to methods of detecting bladder cancer or bladder cancer recurrence. The methods involve identifying a cutoff level for a protein biomarker parameter to provide a predetermined sensitivity for an assay, in which the measured biomarker parameter values below a defined cutoff level is indicative of the absence of cancer and measured biomarker parameter values above a defined cutoff level are indicative of the presence of cancer. The method can also involve establishing a cutoff level for two or more nucleic acid markers in which the nucleic acid markers increase the specificity of the assay without decreasing the sensitivity of the assay, and in which the cutoff level is indicative of the absence of cancer. Methods can further involve conducting an assay in a sample to determine a level of a protein marker and a level of a nucleic acid markers and identifying the sample as positive for cancer recurrence if the level of the protein marker and the nucleic acid markers are greater than their respective cutoff levels. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11154240-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11289206-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11211158-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023147568-A3 |
| priorityDate | 2007-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1253.